News and Publications
Publication Categories
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
Explore how LFA-1 activation with 7HP349 enhances T cell infiltration in cold tumors and synergizes with CTLA-4 blockade for improved cancer immunotherapy. Learn more about its impact on tumor immunity.
Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease
Discover how 7HP349, a novel integrin activator, enhances vaccine efficacy by boosting T cell-mediated immune responses. Learn how this systemic adjuvant improves protection against Chagas disease and other infections.
Immune activators – enhancing cell adhesion to safely improve effectiveness of vaccines & cancer immunotherapies
7 Hills Pharma develops integrin activators like 7HP349 to enhance vaccine efficacy and immunotherapy for cancer. Learn how their breakthrough technology boosts immune response in vulnerable populations.
Integrin-mediated augmentation of antigenic immunity
Explore how 7HP349, a novel integrin activator, enhances immune responses in cancer therapy and vaccine efficacy. Learn about its role in boosting T cell activation, checkpoint blockade, and pathogen-specific immunity with a strong safety profile.
Potentiating immune checkpoint blockade therapeutic efficacy using a small molecule activator of integrin cell adhesion receptors
Discover how the small molecule integrin activator 7HP349 enhances immune checkpoint blockade therapy by promoting T cell infiltration into tumors. Learn about its role in boosting anti-CTLA-4 and anti-PD-L1 efficacy in melanoma and colon cancer models.
Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion
Discover THI0019, the first small molecule agonist of VLA-4 integrin, designed to enhance progenitor cell adhesion and improve stem cell therapy outcomes. Learn how integrin activation can boost cell retention, migration, and engraftment.